How should isosorbide mononitrate (ISMN) be initiated and titrated for a patient with coronary artery disease who needs additional anti‑anginal therapy?

Initiation and Titration of Isosorbide Mononitrate in Coronary Artery Disease

Start with isosorbide mononitrate (ISMN) 30-60 mg once daily in the morning, then titrate to 60-120 mg once daily based on symptom control, avoiding twice-daily dosing to prevent nitrate tolerance. 1

Starting Dose and Timing

Begin ISMN at 30-60 mg once daily taken upon arising in the morning 1. The once-daily morning dosing is critical because:

• It provides 12+ hours of antianginal coverage during waking hours when angina is most likely 1
• It creates a nitrate-free interval overnight (12+ hours) that prevents tolerance development 2, 3, 4
• Extended-release formulations reach peak levels at 3-4 hours post-dose and maintain therapeutic concentrations for 12 hours 1

Titration Strategy

If symptoms persist after 2 weeks on 60 mg, increase to 120 mg once daily 1. Clinical trial data demonstrates:

• 30-60 mg doses showed significant acute antianginal effects but lost efficacy by day 42 of continuous therapy
• 120-240 mg doses maintained significant increases in exercise tolerance at both 4 and 12 hours post-dosing through 42 days of treatment 1
• Dose-proportional increases in drug exposure occur without changes in half-life 1

Maximum dose is 240 mg once daily, though 120 mg is typically sufficient for most patients 1.

Critical Pitfall: Avoiding Tolerance

Never prescribe ISMN twice daily or use continuous 24-hour nitrate coverage—this rapidly induces complete tolerance within 24-48 hours 2, 3, 4. The evidence is unequivocal:

• Continuous nitrate exposure (ISDN 40 mg four times daily or 24-hour transdermal patches) causes complete loss of antianginal effects within 8-12 hours 3
• Tolerance is reversible with a nitrate-free interval of 10-14 hours 2, 4
• The twice-daily regimen (20 mg morning and 7 hours later) mentioned in older studies 2 is inferior to modern once-daily extended-release formulations

Managing Side Effects

Headaches occur commonly but indicate drug activity 1. Instruct patients:

• Do NOT alter the dosing schedule to avoid headaches—this causes loss of efficacy 1
• Treat with aspirin or acetaminophen, which relieves headache without reducing antianginal effect 1
• Headaches typically diminish after several days of continued use

Monitor for orthostatic hypotension, especially:

• In volume-depleted patients
• When combined with other vasodilators, alcohol, or calcium channel blockers 1
• Immediately after rising from sitting/lying positions 1

Integration with Guideline-Directed Therapy

ISMN should be tailored to patient characteristics, comorbidities, and underlying angina pathophysiology 5. Consider:

• First-line for vasospastic angina: Long-acting nitrates are second-line after calcium channel blockers 6
• Add-on therapy in stable angina: Use when beta-blockers or calcium channel blockers alone are insufficient 5
• Avoid in hypertrophic cardiomyopathy: Nitrates may worsen angina in this population 1

Monitoring Response

Assess efficacy at 2-4 weeks by:

• Reduction in anginal attack frequency
• Decreased sublingual nitroglycerin consumption
• Improved exercise tolerance (if formally tested)

If inadequate response on 120 mg once daily, add a second antianginal class rather than increasing ISMN further or splitting doses 5.

Special Populations

Elderly patients (≥65 years): No dose adjustment needed for 60 mg, but may show 30% lower clearance at 120 mg doses—monitor for hypotension but maintain once-daily dosing 1.

Long-term Considerations

Emerging evidence suggests chronic ISMN may cause endothelial dysfunction and oxidative stress 7, 8, though these studies conflict with decades of clinical use. This does not change the recommendation for ISMN use when indicated, but reinforces the importance of comprehensive secondary prevention (aspirin, high-intensity statin targeting LDL-C <55 mg/dL, ACE inhibitor if indicated) 5.